

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

*(use as many sheets as necessary)*

Sheet	1	of	2
-------	---	----	---

**Complete if Known**

Application Number	09/912,252
--------------------	------------

Filing Date	July 25, 2001
-------------	---------------

First Named Inventor	Croze et al
----------------------	-------------

Group Art Unit	1636
----------------	------

Examiner Name	Q. Nguyen
---------------	-----------

Attorney Docket Number	BERLX-0079
------------------------	------------

## U.S. PATENT DOCUMENTS

[illegible]

## FOREIGN PATENT DOCUMENTS

[illegible]

Examiner Signature		Date Considered	9/10/04
-----------------------	---	--------------------	---------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



Please type a plus sign (+) inside this box → ☐

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 2

### Complete if Known

Application Number	09/912,252
Filing Date	July 25, 2001
First Named Inventor	Croze et al.
Group Art Unit	1636
Examiner Name	Q. Nguyen
Attorney Docket Number	BERLX-0079

### NON-PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
QW		Fish et al., Biochemical and Biophysical Research Communications, Vol. 112, No. 2, April 29, 1983, "Human Leukocyte Interferon Subtypes Have Different Antiproliferative And Antiviral Activities on Human Cells"	
		Luis M. De La Maza, Infection and Immunity, March 1985, Vol. 47, No. 3, pp. 719-722, "Interferon-Induced Inhibition of Chlamydia trachomatis: Dissociation from Antiviral and Antiproliferative Effects"	
		Aye-Aye Khine, J. Of Cellular Physiology (2000) Vol. 182, pp. 97-108, "Functional Significance of Globotriaosyl Ceramide in Interferon $\alpha_2$ /Type 1 Interferon Receptor-Mediated Antiviral Activity"	
		Hiroomi Tada et al., The Journal of Clinical Investigation, July 2001 Vol. 108, No. 1, pp. 83-95, "Systemic IFN- $\beta$ gene therapy results in long-term survival in mice with established colorectal liver metastases"	
		Guangwen Cao et al., Cancer Gene Therapy, Vol. 8 No. 7 (2001), pp. 497-505, "Adenovirus-mediated interferon- $\beta$ gene therapy suppresses growth and metastasis of human prostate cancer in nude mice"	
		Mandell R. et al., American Association for Cancer Research, Vol. 38, March 1, 1997 p. 381 XP002074718, "Gene Therapy of Cancer by Retroviral Transfer and Expression of the rat sodium iodine symporter (NIS)"	
		Kim, S.H. et al., An International Journal On Genes And Genomes, September 1, 1997, Vol. 196, No. 1-2 pp. 279-286 XP004126355, "Mammalian type I interferon receptors consists of two subunits"	
		Russell-Harde Dean et al., Journal of Biological Chemistry, (1995) Vol. 270, No. 44, pp. 26033-26036 XP002184662 "Reconstitution of a high affinity binding site for type I interferons"	
QW		Pfeffer Lawrence M. et al., (1997), Vol. 272, No. 17, pp. 11002-1105, XP002184663, "The short form of the interferon alpha/beta receptor chain 2 acts as a dominant negative for type I interferon action"	

Examiner Signature		Date Considered	9/10/04
--------------------	--	-----------------	---------

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450.